Pfizer on Thursday formally applied for emergency use authorization with the Food and Drug Administration for a smaller dose of its COVID-19 vaccine for use in children aged between 5 and 11. Thursday ...
The U.S. Food and Drug Administration has approved emergency use authorization for a booster shot of the Pfizer-BioNTech vaccine to be given at least six months after completion of the second dose for ...
Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...
Pfizer is seeking emergency use authorization for its COVID-19 booster vaccine shot for children ages 5 to 11. The company said it submitted its application to the Food and Drug Administration on ...
BioNTech is the Marketing Authorization Holder for BNT162b2 Wild Type and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the United States, the European Union, the United Kingdom, Canada and other ...
Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 12 years of age and older as a single ...
Pfizer announced Tuesday that it is seeking emergency use authorization from the US Food and Drug Administration for its experimental antiviral Covid-19 pill, known as PF-07321332 or Paxlovid. Pfizer ...
Drugmaker Pfizer said Tuesday that it plans to apply for emergency-use authorization from the Food and Drug Administration for its COVID-19 vaccine in November, once safety milestones are achieved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results